REZENOPY™ Secures Major Health Plan Coverage, Expanding Access to 100M+ Lives Ahead of July Launch
SCNX sits 58% above its 52-week low of $0.238 on light trading volume (0.1× avg).
Summary
Scienture Holdings secured formulary coverage for its REZENOPY™ nasal spray with a large national health plan, potentially expanding access to over 100 million covered lives. This critical development, alongside the expansion of its commercial team, positions the company for its planned mid-July commercial launch. The news is highly significant given the company's severe financial distress, including a recent 'going concern' disclosure and minimal current revenue. Securing this broad market access for REZENOPY™ in the ~$144 million annual U.S. naloxone market is a crucial step towards generating much-needed revenue. The market will now watch for the actual sales performance post-launch.
At the time of this announcement, SCNX was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.